Tags : OTEZLA

Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study

Tuba Khan May 7, 2020

Shots: Shots: The P-III ADVANCE study involves assessing of Otezla (apremilast, 30mg, bid for 16wks.) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis. Later, patients will receive Otezla during an open-label extension phase @32wks. The P-III ADVANCE study results: @16wks., improvement in its 1EPs of sPGA score; achieve 2EPs i.e, […]Read More

Regulatory

Amgen Receives Health Canada’s Marketing Authorization Transfer of Otezla for

Tuba Khan February 13, 2020

Shots: Health Canada’s marketing authorization transfer of Otezla from Celgene follows Amgen’s acquisition of the global rights of Otezla completed in Nov’2019 The addition of Otezla bolster Amgen’s portfolio of innovative biologics and biosimilar products and complements its expertise in mod. to sev. PsO and active PsA Otezla is a selective PDE4 inhibitor, inhibiting the […]Read More

Pharma

Amgen to Acquire Celgene’s Otezla (apremilast) for $13.4B

Tuba Khan August 26, 2019

Shots: Amgen to acquire Otezla for $13.4B in cash and will receive its related intellectual property including patents primarily covering apremilast with all assets and liabilities related to Otezla along with Celgene’s employees associated with the Otezla BMS to divest Otezla in order to get regulatory approval for its pending Celgene merger. The closing of […]Read More

Regulatory

Celgene’s Otezla (apremilast) Receives FDA’s Approval for Oral Ulcers Associated

Tuba Khan July 22, 2019

Shots: The approval is based on P-III RELIEF study results assessing Otezla (30mg, bid) vs PBO in 207 patients in a ratio (1:1) with Behçet’s Disease with active oral ulcers prior treated with at least one nonbiologic medication and systemic therapy for 64wks. across 10 countries The P-III RELIEF study results: @12wks. reduction in pain […]Read More

Pharma

Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the

Tuba Khan June 25, 2019

Shots: BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly In Jan’2019, BMS announced to acquire Celgene with its expected closing of the transaction in H2’19 or H1’20. The divestiture of Otezla will accelerate BMS post-closing deleveraging plans Otezla is a PDE4 inhibitor, […]Read More

Pharma

Celgene Reports Improvement in Patients with Moderate-to-Severe Plaque Psoriasis with

Vartika Singh September 13, 2018

Shots: Results: ESTEEM 1, 2: NAPSI@32wk (31.3% vs 15.5), DLQI @16wks. (28.7% vs 8.1%); UNVEIL: NAPSI@32wks. (36.2% vs 37.2%), DLQI@16wks. (23.7% vs 10.6%) Though, Post-hoc analysis revealed that OTEZLA was not able to achieve PASi75@32/52wks A 5-year extension study of ESTEEM 1 and 2 is ongoing. OTEZLA (apremilast) (PDE4i) marketed as 30 mg PO indicated […]Read More

Amgen Collaborates with Evoq to Develop Novel Therapies for Autoimmune Disorders

Gilead Collaborates with VIR to Evaluate Combination Therapy for Chronic Hepatitis B Virus

Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

Boehringer Ingelheim Collaborates with Cure Genetics to Develop Next-Generation Liver-Targeted Gene Therapy

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Henlius’ HLX15 (biosimilar, daratumumab) Receives IND Approval for Multiple Myeloma in China

Celltrion Report Results of CT-P59 in P-II/III Study for COVID-19

The US Government to Purchase Additional Doses of Regeneron’s Casirivimab and Imdevimab to Combat COVID-19

Tessa’s CD30 CAR-T Therapy Receives EMA’s PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma

Genmab’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) Receives the US FDA’s Approval for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Nanobiotix Presents Results of NBTXR3 (PEP503) in P-Ib/II Study for Rectal Cancer at ASCO-GI 2021

Tags : OTEZLA

Amgen Reports Results of Otezla (apremilast) in P-III ADVANCE Study

Amgen Receives Health Canada’s Marketing Authorization Transfer of Otezla for

Amgen to Acquire Celgene’s Otezla (apremilast) for $13.4B

Celgene’s Otezla (apremilast) Receives FDA’s Approval for Oral Ulcers Associated

Bristol-Myers Squibb to Divest Celgene’s Otezla (apremilast) to Gain the

Celgene Reports Improvement in Patients with Moderate-to-Severe Plaque Psoriasis with

Latest Posts

ViewPoints Interview: Kaia Health’s Jonas Duss Shares Insights on COPD Pulmonary Rehabilitation App

Philips to Acquire Capsule Technologies for ~$635M

Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia

Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

Tags : OTEZLA

Latest Posts

Categories

Related Topics